You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 21, 2024

Losartan potassium - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for losartan potassium and what is the scope of patent protection?

Losartan potassium is the generic ingredient in two branded drugs marketed by Organon, Aiping Pharm Inc, Alembic Pharms Ltd, Apotex Corp, Aurobindo Pharma, Chartwell Rx, Granules, Hetero Labs Ltd V, Hikma, Hisun Pharm Hangzhou, Ipca Labs Ltd, Jubilant Cadista, Lupin Ltd, Macleods Pharms Ltd, Micro Labs, MSN, Mylan, Prinston Inc, Strides Pharma, Teva, Torrent Pharms, Unichem, Watson Labs, and Zydus Pharms Usa Inc, and is included in twenty-four NDAs. Additional information is available in the individual branded drug profile pages.

There are thirty-eight drug master file entries for losartan potassium. Forty-seven suppliers are listed for this compound.

Drug Prices for losartan potassium

See drug prices for losartan potassium

Drug Sales Revenue Trends for losartan potassium

See drug sales revenues for losartan potassium

Recent Clinical Trials for losartan potassium

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Gadjah Mada UniversityPhase 1/Phase 2
Second Affiliated Hospital, School of Medicine, Zhejiang UniversityN/A
Massachusetts General HospitalEarly Phase 1

See all losartan potassium clinical trials

Pharmacology for losartan potassium
Medical Subject Heading (MeSH) Categories for losartan potassium

US Patents and Regulatory Information for losartan potassium

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hetero Labs Ltd V LOSARTAN POTASSIUM losartan potassium TABLET;ORAL 203835-001 Aug 12, 2015 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Apotex Corp LOSARTAN POTASSIUM losartan potassium TABLET;ORAL 090790-001 Oct 6, 2010 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Macleods Pharms Ltd LOSARTAN POTASSIUM losartan potassium TABLET;ORAL 202230-002 May 30, 2012 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Chartwell Rx LOSARTAN POTASSIUM losartan potassium TABLET;ORAL 077424-001 Oct 6, 2010 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for losartan potassium

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Organon COZAAR losartan potassium TABLET;ORAL 020386-001 Apr 14, 1995 ⤷  Sign Up ⤷  Sign Up
Organon COZAAR losartan potassium TABLET;ORAL 020386-003 Oct 13, 1998 ⤷  Sign Up ⤷  Sign Up
Organon COZAAR losartan potassium TABLET;ORAL 020386-002 Apr 14, 1995 ⤷  Sign Up ⤷  Sign Up
Organon COZAAR losartan potassium TABLET;ORAL 020386-002 Apr 14, 1995 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.